Overview

Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to study the pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal disease.

Phase:

Phase 2

Details

Lead Sponsor:

Radboud University

Treatments:

Anidulafungin
Echinocandins